Terms: = Leukemia AND KAT6A AND Treatment
5 results:
1. Discovery of N-(2-oxoethyl) sulfanilamide-derived inhibitors of kat6a (MOZ) against leukemia by an isostere strategy.
Duan Y; Zhao Y; Li Z; Liu Z; Wang M; Wang X; Sun M; Song C; Yao Y
Eur J Med Chem; 2023 Nov; 260():115770. PubMed ID: 37651878
[TBL] [Abstract] [Full Text] [Related]
2. A Case of Neonatal Myeloid Sarcoma.
Burdick H; Bormann J; Wagner K; Kerkvliet A
S D Med; 2022 Sep; 75(9):390-391. PubMed ID: 36881822
[TBL] [Abstract] [Full Text] [Related]
3. kat6a and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.
Yan F; Li J; Milosevic J; Petroni R; Liu S; Shi Z; Yuan S; Reynaga JM; Qi Y; Rico J; Yu S; Liu Y; Rokudai S; Palmisiano N; Meyer SE; Sung PJ; Wan L; Lan F; Garcia BA; Stanger BZ; Sykes DB; Blanco MA
Cancer Discov; 2022 Mar; 12(3):792-811. PubMed ID: 34853079
[TBL] [Abstract] [Full Text] [Related]
4. [Acute leukemia of infants and neonates].
Eguchi M
Rinsho Ketsueki; 2021; 62(8):1308-1318. PubMed ID: 34497221
[TBL] [Abstract] [Full Text] [Related]
5. Acute Myeloid leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy.
Conneely SE; Stevens AM
Curr Oncol Rep; 2021 Jan; 23(2):16. PubMed ID: 33439382
[TBL] [Abstract] [Full Text] [Related]
